Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 12
1998 26
1999 62
2000 96
2001 146
2002 126
2003 155
2004 166
2005 220
2006 214
2007 233
2008 259
2009 252
2010 312
2011 316
2012 321
2013 359
2014 334
2015 360
2016 339
2017 353
2018 329
2019 386
2020 453
2021 410
2022 435
2023 400
2024 370
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,667 results

Results by year

Filters applied: . Clear all
Page 1
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Dorman SE, et al. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. N Engl J Med. 2021. PMID: 33951360 Free PMC article. Clinical Trial.
In one 4-month regimen, rifampin was replaced with rifapentine; in the other, rifampin was replaced with rifapentine and ethambutol with moxifloxacin. The primary efficacy outcome was survival free of tuberculosis at 12 months. ...Adverse events of grade 3 or higher occurr …
In one 4-month regimen, rifampin was replaced with rifapentine; in the other, rifampin was replaced with rifapentine and ethambutol with …
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
In stage 2 of the trial, a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) was compared with a 9-to-20-month standard-care regimen. The primary outcome was an unfavorable status (a composite of death, treatment failure, treatment discontinua …
In stage 2 of the trial, a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) was compared with a 9-to-2 …
Omadacycline for Community-Acquired Bacterial Pneumonia.
Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Stets R, et al. N Engl J Med. 2019 Feb 7;380(6):517-527. doi: 10.1056/NEJMoa1800201. N Engl J Med. 2019. PMID: 30726692 Clinical Trial.
RESULTS: The intention-to-treat population included 386 patients in the omadacycline group and 388 patients in the moxifloxacin group. Omadacycline was noninferior to moxifloxacin for early clinical response (81.1% and 82.7%, respectively; difference, -1.6 percentag …
RESULTS: The intention-to-treat population included 386 patients in the omadacycline group and 388 patients in the moxifloxacin group …
2021 European guideline on the management of Mycoplasma genitalium infections.
Jensen JS, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M. Jensen JS, et al. J Eur Acad Dermatol Venereol. 2022 May;36(5):641-650. doi: 10.1111/jdv.17972. Epub 2022 Feb 19. J Eur Acad Dermatol Venereol. 2022. PMID: 35182080
Second-line treatment and treatment for uncomplicated macrolide-resistant M. genitalium infection: Moxifloxacin 400 mg od for 7 days (oral). Third-line treatment for persistent M. genitalium infection after azithromycin and moxifloxacin: Doxycycline or minocycline 1 …
Second-line treatment and treatment for uncomplicated macrolide-resistant M. genitalium infection: Moxifloxacin 400 mg od for 7 days …
Reply.
Shorstein NH, Gardner S. Shorstein NH, et al. J Cataract Refract Surg. 2020 Jan;46(1):163-164. doi: 10.1097/j.jcrs.0000000000000005. J Cataract Refract Surg. 2020. PMID: 32050250 No abstract available.
Reply.
Stulting RD, Trattler WB, Woolfson JM, Rubinfeld RS. Stulting RD, et al. J Cataract Refract Surg. 2019 Jun;45(6):892-893. doi: 10.1016/j.jcrs.2019.04.021. J Cataract Refract Surg. 2019. PMID: 31146951 No abstract available.
Effect of Topical Antibiotics on Duration of Acute Infective Conjunctivitis in Children: A Randomized Clinical Trial and a Systematic Review and Meta-analysis.
Honkila M, Koskela U, Kontiokari T, Mattila ML, Kristo A, Valtonen R, Sarlin S, Paalanne N, Ikäheimo I, Pokka T, Uhari M, Renko M, Tapiainen T. Honkila M, et al. JAMA Netw Open. 2022 Oct 3;5(10):e2234459. doi: 10.1001/jamanetworkopen.2022.34459. JAMA Netw Open. 2022. PMID: 36194412 Free PMC article.
RESULTS: The randomized clinical trial included 88 participants (46 [52%] girls), of whom 30 were randomized to moxifloxacin eye drops (mean [SD] age, 2.8 [1.6] years), 27 to placebo eye drops (mean [SD], age 3.0 [1.3] years), and 31 to no intervention (mean [SD] age, 3.2 …
RESULTS: The randomized clinical trial included 88 participants (46 [52%] girls), of whom 30 were randomized to moxifloxacin eye drop …
Reply.
Melega MV, Alves M, Cavalcanti Lira RP, Cardoso da Silva I, Ferreira BG, Assis Filho HLG, Pedreira Chaves FR, Martini AAF, Dias Freire LM, Reis RD, Leite Arieta CE. Melega MV, et al. J Cataract Refract Surg. 2019 Jun;45(6):890-891. doi: 10.1016/j.jcrs.2019.03.027. J Cataract Refract Surg. 2019. PMID: 31146948 No abstract available.
Reducing the risk of endophthalmitis.
Mamalis N. Mamalis N. J Cataract Refract Surg. 2019 Sep;45(9):1217-1218. doi: 10.1016/j.jcrs.2019.07.025. J Cataract Refract Surg. 2019. PMID: 31470938 No abstract available.
Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia.
He YS, Yang M, Liu G, Ji J, Qian SY. He YS, et al. Pediatr Pulmonol. 2023 Jul;58(7):2017-2024. doi: 10.1002/ppul.26426. Epub 2023 Apr 26. Pediatr Pulmonol. 2023. PMID: 37098833
A multidisciplinary team reviewed all adverse events and determined their relationship with moxifloxacin. RESULTS: A total of 52 children with SRMPP were included in this study (31 in the moxifloxacin group and 21 in the azithromycin group). ...CONCLUSION: Moxifl …
A multidisciplinary team reviewed all adverse events and determined their relationship with moxifloxacin. RESULTS: A total of 52 chil …
6,667 results